ClinicalTrials.gg
CompletedNCT03376529Updated Jan 5, 2018

Phase 1 Study to Evaluate DDI, PK, Safety, Tolerability of SPR741

A Phase 1 interventional study of SPR741 and Ceftazidime in Healthy Volunteers, sponsored by Spero Therapeutics. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-01-05.

Sponsored by Spero Therapeutics · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
27
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This is a Phase 1, single-center, multi-arm, open-label, randomized, three-period, crossover study to evaluate the drug-drug interaction, pharmacokinetics, safety, and tolerability of a single dose of SPR741 combined with each of 3 different partner antibiotics (ceftazidime or piperacillin/tazobactam or aztreonam) in healthy volunteers. Participants will be administered single doses of SPR741 alone, a single dose of SPR741 in combination with 1 of 3 different partner antibiotics, and the partner antibiotic alone in a randomized sequence. Twenty-seven (27) adult male and female normal healthy participants 18 to 55 years of age are planned to participate in the study. Women of childbearing potential will not be eligible to participate.

Read the detailed description

This is a Phase 1, single-center, multi-arm, open-label, randomized, three-period crossover study to evaluate the drug-drug interaction, pharmacokinetics, safety, and tolerability of a single dose of SPR741 combined with each of 3 different partner antibiotics (ceftazidime, piperacillin/tazobactam, and aztreonam) in healthy volunteers. Participants will be administered a single dose of SPR741 alone, a single dose of SPR741 in combination with 1 of the 3 different partner antibiotics, and a single dose of the partner antibiotic alone in a randomized sequence. Twenty-seven (27) adult male and female normal healthy participants 18 to 55 years of age are planned to participate in the study. Women of childbearing potential will not be eligible to participate. The study will consist of 3 phases: a screening phase, a treatment phase, and a follow-up phase.

The 3 treatment arms will be enrolled and dosed in parallel or in a staggered manner, as needed for scheduling.

All participants in the study will be monitored for safety after administration of the last dose of investigational product.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • safety
  • tolerability
  • pharmacokinetics
  • drug-drug interaction
  • SPR741
  • antibiotic
03

In context

Lead sponsor

Spero Therapeutics is the lead sponsor of 22 studies on the registry; none are open to participants now.

Of its 15 completed or terminated interventional studies of FDA-regulated products, 3 (20%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy adult males and/or females (of non-), 18 to 55 years of age (inclusive) at the time of screening;
  2. ≥ 18.5 and ≤ 29.9 (kg/m2) and weight between 55.0 and 100.0 kg (inclusive);
  3. Medically healthy without abnormalities at the screening visit or Day -1, including:

    1. Physical examination, vital signs. Vital signs include temperature, heart rate, respiratory rate, and blood pressure;
    2. Triplicate ECGs taken at least 1 minute apart with interval duration less than 450 msec obtained as an average from the triplicate screening and pre-dose Day 1 ECGs after at least 5 min in a semi-supine quiet rest;
    3. /hematocrit, white blood cell (WBC) count, and count equal to or greater than the lower limit of normal range of the reference laboratory;
    4. Creatinine, BUN, and AST equal to or less than the for the reference laboratory; results of all other clinical chemistry and urine analytes without any clinically significant abnormality.

    Discussion between the PI and the Medical Monitor (MM) is encouraged regarding the potential significance of any laboratory value that is outside of the normal range during the pre-dose period.

  4. Be non-smokers (including tobacco, e-cigarettes or marijuana) for at least 1 month prior to participation in the study;
  5. Willing and able to provide written ;
  6. Be willing and able to comply with all study assessments and adhere to the protocol schedule;
  7. Have suitable venous access for drug administration and blood sampling;
  8. If female, be of non-childbearing potential (e.g. as demonstrated by FSH or surgical sterilization i.e., tubal ligation or hysterectomy). Provision of documentation is not required for female sterilization, verbal confirmation is adequate;
  9. If male, a willingness not to donate sperm and if engaging in sexual intercourse with a female partner who could become pregnant, a willingness to use a condom in addition to having the female partner use a highly effective method of (such as an intrauterine device, diaphragm, oral contraceptives, injectable progesterone, subdermal implants, or a tubal ligation). This criterion applies to males (and/or female partners) who are surgically sterile and must be followed from the time of first study drug administration until 90 days after the final administration of study drug.

Exclusion criteria

Exclusion Criteria:

  1. History or presence of significant cardiovascular, pulmonary, hepatic, renal, hematological, gastrointestinal, endocrine, immunologic, dermatologic or neurological disease, including any acute illness or surgery within the past 3 months determined by the PI to be ;
  2. History of known or suspected Clostridium difficile infection;
  3. History of seizure disorders;
  4. Positive urine drug/alcohol testing at screening or check-in (Day -1);
  5. Positive testing for , or ;
  6. History of substance abuse or alcohol abuse (defined as those who consume more than 14 units of alcohol per week, and where this consumption is spread over less than 3 days, or those who regularly (weekly) consumed excessive amounts of alcohol (>8 units for men and >6 units for women in one consumption, excessive amounts as defined by the UK National Office of Statistics) within the previous 5 years;
  7. Use of any prescription medication or any over-the-counter medication, herbal products, vitamins, diet aids or hormone supplements within 7 days prior to randomisation;
  8. Documented reaction or anaphylaxis to any medication;
  9. Donation of blood or plasma within 30 days prior to randomisation, or loss of whole blood of more than 500 mL within 30 days prior to randomisation, or receipt of a blood transfusion within 1 year of study enrollment;
  10. Participation in a New Chemical Entity clinical study within the previous 3 months or a marketed drug clinical study within the 30 days before the first dose of IMP. ( between studies is defined as the period of time elapsed between the last dose of the previous study and the first dose of the next study).
  11. Any other condition or prior therapy, which, in the opinion of the PI, would make the volunteer unsuitable for this study, including unable to cooperate fully with the requirements of the study protocol or likely to be non-compliant with any study requirements.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
27 participants (actual)

Study arms

  • Experimental
    SPR741/Ceftazidime (N=9)

    Nine (9) participants will be enrolled and assigned to receive SPR741 400 mg IV over 1 hour, SPR741 400 mg IV over 1 hour + ceftazidime1.0 gram IV over 1 hour, and ceftazidime 1.0 gram IV over 1 hour in a randomized sequence. One treatment will be administered during each of 3 dose periods within the assigned treatment arm.

    Drug: SPR741 · Drug: Ceftazidime

  • Experimental
    SPR741/Piperacillin/tazobactam (N=9)

    Nine (9) participants will be enrolled and assigned to receive SPR741 400 mg IV over 1 hour, SPR741 400 mg IV over 1 hour + piperacillin/tazobactam 4.5 grams IV over 1 hour, and piperacillin/tazobactam 4.5 grams IV over 1 hour in a randomized sequence. One treatment will be administered during each of 3 dose periods within the assigned treatment arm.

    Drug: SPR741 · Drug: Piperacillin/tazobactam

  • Experimental
    SPR741/Aztreonam (N=9)

    Nine (9) participants will be enrolled and assigned to receive SPR741 400 mg IV over 1 hour, SPR741 400 mg IV over 1 hour + aztreonam 1.0 gram IV over 1 hour, and aztreonam 1.0 gram IV over 1 hour in a randomized sequence. One treatment will be administered during each of 3 dose periods within the assigned treatment arm.

    Drug: SPR741 · Drug: Aztreonam

Interventions

  • DrugSPR741

    400 mg IV over 1 hour

  • 1.0 gram IV over 1 hour

  • DrugPiperacillin/tazobactam

    4.5 grams IV over 1 hour

  • 1.0 gram IV over 1 hour

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics: Maximum concentration (Cmax)

    Blood draws will be taken pre-dose (within 10 minutes), 30 minutes following the start of infusion, end of infusion and at 75, 90, 105, and 120 minutes, 4, 8, 12, and 24 hours following start of infusion.

    Time frame: Days 1 to 2, Days 4 to 5, Days 7 to 8

  2. Pharmacokinetics: Area under the concentration-time curve from time 0 to last measurable time-point (AUC0-t)

    Blood draws will be taken pre-dose (within 10 minutes), 30 minutes following the start of infusion, end of infusion and at 75, 90, 105, and 120 minutes, 4, 8, 12, and 24 hours following start of infusion.

    Time frame: Days 1 to 2, Days 4 to 5, Days 7 to 8

  3. Pharmacokinetics: Area under the concentration-time curve from time 0 to infinity (AUC0-inf)

    Blood draws will be taken pre-dose (within 10 minutes), 30 minutes following the start of infusion, end of infusion and at 75, 90, 105, and 120 minutes, 4, 8, 12, and 24 hours following start of infusion.

    Time frame: Days 1 to 2, Days 4 to 5, Days 7 to 8

  4. Pharmacokinetics: Time to maximum concentration (Tmax)

    Blood draws will be taken pre-dose (within 10 minutes), 30 minutes following the start of infusion, end of infusion and at 75, 90, 105, and 120 minutes, 4, 8, 12, and 24 hours following start of infusion.

    Time frame: Days 1 to 2, Days 4 to 5, Days 7 to 8

  5. Pharmacokinetics: Terminal Elimination Rate Constant (kel)

    Blood draws will be taken pre-dose (within 10 minutes), 30 minutes following the start of infusion, end of infusion and at 75, 90, 105, and 120 minutes, 4, 8, 12, and 24 hours following start of infusion.

    Time frame: Days 1 to 2, Days 4 to 5, Days 7 to 8

  6. Pharmacokinetics: Terminal half-life (t1/2)

    Blood draws will be taken pre-dose (within 10 minutes), 30 minutes following the start of infusion, end of infusion and at 75, 90, 105, and 120 minutes, 4, 8, 12, and 24 hours following start of infusion.

    Time frame: Days 1 to 2, Days 4 to 5, Days 7 to 8

  7. Pharmacokinetics: Terminal clearance (CL)

    Blood draws will be taken pre-dose (within 10 minutes), 30 minutes following the start of infusion, end of infusion and at 75, 90, 105, and 120 minutes, 4, 8, 12, and 24 hours following start of infusion.

    Time frame: Days 1 to 2, Days 4 to 5, Days 7 to 8

  8. Pharmacokinetics: Volume of distribution (Vd)

    Blood draws will be taken pre-dose (within 10 minutes), 30 minutes following the start of infusion, end of infusion and at 75, 90, 105, and 120 minutes, 4, 8, 12, and 24 hours following start of infusion.

    Time frame: Days 1 to 2, Days 4 to 5, Days 7 to 8

Secondary outcomes

  1. Safety measures: adverse events (AEs)

    The types and frequency of AEs

    Time frame: Day -1 to Day 9

  2. Safety measures: Summary of type and frequency of concomitant medication

    The type and frequency of medications used will be summarized

    Time frame: Day -1 to Day 9

  3. Safety measures: change in temperature (C/F)

    Change from baseline to end of study

    Time frame: Day -1 to Day 9

  4. Safety measures: change in blood pressure (mmHg)

    Change from baseline to end of study

    Time frame: Day -1 to Day 9

  5. Safety measures: change in heart rate (beats per minute)

    Change from baseline to end of study

    Time frame: Day -1 to Day 9

  6. Safety measures: abnormal, clinically significant physical exam findings

    Change from baseline to end of study

    Time frame: Day -1 to Day 9

  7. Safety measures: abnormal, clinically significant changes in electrocardiogram parameter (RR Interval)

    Change from baseline to end of study

    Time frame: Day -1 to Day 9

  8. Safety measures: abnormal, clinically significant changes in electrocardiogram parameter (P wave)

    Change from baseline to end of study

    Time frame: Day -1 to Day 9

  9. Safety measures: abnormal, clinically significant changes in electrocardiogram parameter (PR Interval)

    Change from baseline to end of study

    Time frame: Day -1 to Day 9

  10. Safety measures: abnormal, clinically significant changes in electrocardiogram parameter (QRS)

    Change from baseline to end of study

    Time frame: Day -1 to Day 9

  11. Safety measures: abnormal, clinically significant changes in electrocardiogram parameter (ST Segment)

    Change from baseline to end of study

    Time frame: Day -1 to Day 9

  12. Safety measures: abnormal, clinically significant changes in electrocardiogram parameter (T Wave)

    Change from baseline to end of study

    Time frame: Day -1 to Day 9

  13. Safety measures:abnormal, clinically significant changes in urinalysis from baseline to end of study

    Change from baseline to end of study

    Time frame: Day -1 to Day 9

  14. Safety measures: abnormal, clinically significant hematology changes from baseline to end of study

    Change from baseline to end of study

    Time frame: Day -1 to Day 9

  15. Safety measures: abnormal, clinically significant serum chemistry changes from baseline to end of study

    Change from baseline to end of study

    Time frame: Day -1 to Day 9

07

Study locations

1 site
  • Simbec Research, Ltd.
    Merthyr Tydfil,, Mid Glamorgan CF48 4DR, United Kingdom
08

References and documents

Publications

  • Eckburg PB, Lister T, Walpole S, Keutzer T, Utley L, Tomayko J, Kopp E, Farinola N, Coleman S. Safety, Tolerability, Pharmacokinetics, and Drug Interaction Potential of SPR741, an Intravenous Potentiator, after Single and Multiple Ascending Doses and When Combined with beta-Lactam Antibiotics in Healthy Subjects. Antimicrob Agents Chemother. 2019 Aug 23;63(9):e00892-19. doi: 10.1128/AAC.00892-19. Print 2019 Sep. PubMed 31262767 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2017 to primary completion in Dec 2017, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 5, 2017
First posted
Dec 18, 2017
StartActual
Nov 10, 2017
Primary completionActual
Dec 19, 2017
CompletionActual
Dec 20, 2017
Last update
Jan 5, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 5, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03376529
Lead sponsor
Spero Therapeutics
Collaborators
Simbec Research, QPS Holdings LLC
Responsible party
Sponsor
First posted
Dec 18, 2017
Start date
Nov 10, 2017
Primary completion
Dec 19, 2017
Completion
Dec 20, 2017
Last update
Jan 5, 2018

Study contacts

Annelize Koch, MBChB
principal investigator · Simbec Research

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion